Aberdeen Group
LUCD icon

Aberdeen Group’s Lucid Diagnostics LUCD Stock Holding History

Aberdeen Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.09M Buy
3,822,997
+178,720
+5% +$193K 0.01% 710
2026
Q1 		$4.19M Buy
3,644,277
+186,383
+5% +$237K 0.01% 707
2025
Q4 		$3.77M Buy
3,457,894
+957,894
+38% +$1.07M 0.01% 726
2025
Q3 		$2.52M Buy
+2,500,000
New +$2.73M ﹤0.01% 761

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Aberdeen Group's LUCD Position: Q2 2026 in Review

Aberdeen Group increased its Lucid Diagnostics (LUCD) stake by 4.9% in Q2 2026, buying an estimated $193K and bringing the position to 3,822,997 shares worth $4.09M. The position accounts for 0.01% of the portfolio, ranked #710.

Aberdeen Group first reported a position in LUCD in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.19M in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Aberdeen Group held 3,822,997 shares of Lucid Diagnostics worth $4.09M as of Q2 2026.
  • Aberdeen Group bought 178,720 Lucid Diagnostics shares in Q2 2026, an estimated $193K.
  • Lucid Diagnostics made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #710 holding.
  • Aberdeen Group first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 4 quarters since.
  • Aberdeen Group's Lucid Diagnostics position peaked at $4.19M in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.